Introduction
Children comprise 26% of the United States population but are the target of only 9% of research funds. Given this limited share of research funds, it is both desirable and necessary to establish research priorities. In fact, a clear research agenda can help guide not only pediatric cardiology research but public health policy as well; poor cardiac health at birth and during childhood has repercussions throughout life. For example, health status during the perinatal, postnatal, and childhood periods has a major impact on adult health status: poor cardiac health as a child equates to poor health as an adult.
Elsewhere, we have described a proposed pediatric cardiology research agenda [1, 2, 3 ]. Here, we identify 22 topics and associated research questions that form a comprehensive research agenda. Essential topics and research questions of a comprehensive clinical research agenda in pediatric cardiology are as follows:
(1) The mechanisms of pediatric cardiovascular disease (a) What is the best approach to understand the clinical presentation, diagnostic approaches, and evidence-based management and therapy of pediatric genetic and mitochondrial diseases? (b) What are the importance of oxidative stress and the emerging use of antioxidants in pediatric cardiology? (c) What developments are needed to refine antiinflammatory and immunomodulatory therapies for immune-mediated cardiovascular diseases? (2) Enhanced physiologic and hemodynamic monitoring of pediatric cardiac status and outcomes, including the use of functional echocardiography (3) Establishing birth cohorts to study the natural history of pediatric cardiac diseases and the effects We discuss five areas of pediatric cardiology research in detail, describing several advances illustrating the impact that such research can have on health throughout life. These five areas are: life-course studies of cardiovascular disease, including the epigenetic fetal origins of disease as well as late effects and long-term cardiac consequences; risk factors for pediatric cardiometabolic disease; needed clinical trials and observational studies in pediatric cardiology; the value of physical activity in treating cardiac disease in children; and how to study pediatric cardiac problems and to implement evidencebased findings.
Life-course studies of pediatric cardiovascular disease New information has recently been published on the late cardiovascular effects of anthracycline chemotherapy in long-term survivors of childhood cancer [4 ,5 ] . Anthracycline toxicity remains one of the best-studied environmental exposures during early childhood that is associated with pervasive, persistent, and, in many cases, progressive late cardiotoxicity. Despite improvements in dilated cardiomyopathy soon after anthracycline chemotherapy, especially in girls treated at younger ages and receiving higher doses of anthracycline, longterm follow-up of childhood cancer reveals a restrictive cardiomyopathy, the incidence of which increases with time. Cardiovascular-related morbidity and mortality rates are significantly increased in these patients at 20 and even 30 years after exposure. Radiation therapy is also associated with progressive late cardiovascular toxicity [6 ] .
These studies [4 ,5 ,6 ] illustrate the need for lifecourse analyses of the relationships between early environmental exposures and late cardiovascular effects (Topics 1 through 3, 5 through 10, and 12) in terms of the mechanisms and time course of injury, monitoring issues, screening techniques, epigenetic factors, environmental and genetic susceptibilities, biomarker development, individual and population disparities, and clinical trial designs.
The importance of long-term follow-up of the effects of medications and chronic illnesses for late cardiovascular health and diseases was recently illustrated in a study of HIV-infected children at high risk for cardiovascular diseases in which medications such as antiretroviral therapy and other disease factors markedly increased their risk of these diseases (Topics 3, 5, 6, 9, and 11) [7 ] .
Other clinical situations have shown that otherwise healthy children may be put at risk by maternal exposures in utero. For example, children born to HIV-infected mothers have a persistent and progressive risk for cardiovascular disease, as well as mortality rates that appear to be related to maternal health and exposures, emphasizing the importance of fetal and developmental origins of subsequent disease [8 -11 ]. Furthermore, maternal dietary intake may influence the child's subsequent cardiovascular health or risk. Second-trimester maternal calcium intake is significantly associated with systolic blood pressure during early childhood, for example [12 ] . Thus, the fetal and developmental origins of adult cardiovascular disease and the importance of longer followup studies are parts of the proposed pediatric cardiology clinical research plan (Topics 3 through 6, 11, 12).
Other topics in pediatric cardiology research are also of emerging interest. These topics include developing biomarkers that are validated as surrogate endpoints for clinically significant diseases and understanding the mechanisms of reversible and irreversible myocardial injury during early childhood that may be related to chronic adrenergic stimulation, as might occur in a child on inotropic therapy in a cardiac critical care unit (Topics 1 through 3, 6, and 9) [13 ] . Additionally, research into models of comprehensive long-term care of pediatric cardiology patients with chronic illnesses is now available (Topics 3, 10, 11 ]. In turn, this clustering is associated with the onset of type 2 diabetes and longterm atherosclerotic cardiovascular complications in both childhood and adulthood [19, 20] .
Nearly one million adolescents aged 12-19 years in the United States, or about 4% of the population in this age range, have signs and symptoms of metabolic syndrome [18 ] . Among overweight adolescents, the prevalence is nearly 30%. Among 8-year-old to 11-year-old children, national prevalence estimates of metabolic syndrome risk factors ranged from 2-9%, using two age-adjusted, sex-adjusted, and ethnicity-adjusted definitions [21 ] .
Identifying individual children and adolescents who either are at risk for or who have metabolic syndrome has remained more elusive and controversial. Much of the controversy surrounding metabolic syndrome in children is in its definition [18 ,22] . Definitions of pathological processes are typically based on endpoints. The difficulty in defining these predictors of cardiovascular risk in childhood is that most children have not experienced the endpoint of interest (atherosclerotic cardiovascular disease). Thus, there is technically no single, established operational definition of metabolic syndrome in children [17 ] . The challenge is to set an appropriate cut-point for each risk factor that takes into account age and sex, as well as continuous growth, the onset of puberty, and perhaps ethnic background and setting these cut-points should be a research priority as such. One approach has been to use age-adjusted and sex-adjusted percentiles as the cut-points for these risk factors, which raises the issues of which percentiles maximize both the sensitivity and specificity of the prediction and on what cohort these cut-points are determined: an historical cohort from before the current obesity epidemic, perhaps as far back as the first or second National Health and Nutrition Examination Surveys, or a more current cohort that may potentially be skewed toward higher risk.
The American Heart Association has stated that further research is necessary to define pediatric metabolic syndrome. Specific areas of inquiry include the need to: assess large-scale observational and outcome studies to determine stability and predictive power of future chronic disease (e.g. diabetes and cardiovascular disease); clarify the molecular basis of metabolic syndrome; establish the importance of environmental exposures or toxins in the development of metabolic syndrome; determine the appropriate use of medical management in treating insulin resistance, prehypertension, early vascular changes, elevated triglyceride levels, and low high density lipoprotein cholesterol levels; identify the pathways linking insulin resistance and obesity with other metabolic syndrome components beginning early in life; better understand leptin biology and the mechanisms of weight regulation; assess any genetic predisposition and prenatal and neonatal factors that promote the development of insulin resistance and metabolic syndrome; and determine whether the mechanisms and pathways of metabolic syndrome vary among racial or ethic groups [17 ] .
Only systematic, long-term follow-up of well characterized pediatric cohorts into adulthood will provide the information needed to define appropriate age-specific, sex-specific, and race or ethnicity-specific cardiovascular risks in childhood. Such studies should allow earlier and more aggressive lifestyle interventions as well as more appropriate pharmacologic treatment of these children.
Recent clinical trials and observational studies in pediatric cardiology
Results from the Pediatric Cardiomyopathy Registry (a study funded by the National Heart Lung and Blood Institute since 1995) indicate that children with Duchenne or Becker muscular dystrophy in addition to cardiomyopathy are at greater risk of premature mortality than are children with other causes of cardiomyopathy [23 ] . As a result, regular cardiac evaluations can now be recommended for children with muscular dystrophy early in their presentation to optimize the application of potentially beneficial cardiac therapies.
In 2004, Lipshultz et al. [24] reported the results of a randomized clinical trial in which dexrazoxane, an iron chelator associated with reduced free radical production, prevented or reduced the cardiac injury associated with doxorubicin treatment for childhood acute lymphoblastic leukemia. Although a 2007 report suggested that dexrazoxane increased the incidence of secondary malignancies in children with Hodgkin's disease [25] , a follow-up analysis of the 2004 study of high-risk children with acute lymphoblastic leukemia found that dexrazoxane was not associated with an increased risk of secondary malignant neoplasms [26 ] . The authors of the 2004 study concluded that given the potential importance of dexrazoxane as a cardioprotectant, it should continue to be used and studied in doxorubicin-containing pediatric cancer treatment regimens.
Interest in the use of cardiac biomarkers to evaluate cardiac status in children is increasing (Topic 9). Cardiac troponin T (cTnT) is a serum biomarker associated with myocardial injury from a variety of causes. In a study of 32 otherwise healthy newborns, cTnT levels were elevated in both cord (24 or 76%) and peripheral blood (30 or 94%) and were high enough to be associated with myocardial infarction in two (6%) of these infants [27 ] . Other biomarkers associated with cardiac disease or dysfunctions were also found in smaller proportions of this sample. The authors concluded that sub-clinical myocardial injury occurs in apparently healthy newborns, but whether this injury is pathologic or a response to the stress of the immediate perinatal period or to other prenatal factors remains to be determined.
Another biomarker used to assess cardiac status is N-terminal pro-hormone brain natriuretic peptide (NT-proBNP), which is secreted by myocytes in the cardiac ventricle. This biomarker is elevated in patients with both asymptomatic and symptomatic ventricular dysfunction, including congestive heart failure. Mangat et al. [28 ] found that elevated and rising brain natriuretic peptide (BNP) levels, the active hormone, were associated with both abnormal echocardiographic measurements of left ventricular dysfunction as well as with clinical assessments of cardiac-related disability using either the New York Heart Association or the Ross (for nonambulatory infants) classifications. In children with congestive heart failure, a serum BNP level greater than 290 pg/ml was associated with death, transplantation, or listing for transplantation [28 ] .
Maher et al. [29 ] found that BNP was useful in identifying heart disease in children admitted to emergency departments. The mean BNP level was 3290 pg/ml in children with acute presentations of congenital or acquired heart disease and 17 pg/ml in children with respiratory or other infections. Another recent report found that neuroendocrine (NT-proBNP levels) and inflammatory activation (levels of C-reactive protein, tumor necrosis factor-alpha or soluble tumor necrosis factor receptor II) were associated with more severe symptoms and dilated cardiomyopathy in children with heart failure [30 ] .
The role of physical activity in preventing and treating cardiac disease in children
The benefits of a healthy life style in health and sickness are well documented [21 ] . Substantial evidence currently indicates that among children with chronic disease that can lead to, or is a result of, cardiac dysfunction, structured exercise programs can improve some clinical endpoints and are safe in the right environment.
In light of the rapidly increasing rates of childhood obesity, interest is now even greater in ascertaining its cardiovascular effects in children with and without chronic illness (Topic 11) [31 ] . Children with chronic disease, especially those with cardiac dysfunction, are at risk for sedentary lifestyles and poor nutrition that can lead to overweight and exacerbate or promote cardiac dysfunction [32] . Massin et al.
[32] outlines the atherosclerotic cardiovascular risk of children with congenital heart disease. Up to 25% of children with congenital or acquired heart disease are overweight [33] . Emerging evidence suggests that children with congenital heart disease, cardiomyopathy (congenital or acquired), cardiac transplantation, or metabolic cardiac risk (secondary to obesity) can benefit from increased physical activity and improved nutrition (Topic 12) [34] .
Children with congenital heart disease can show baseline deconditioning, regardless of previous surgical repair. Children with hypoplastic left heart syndrome had a progressive age-related decline in exercise performance regardless of surgical strategy with children aged 13-17 years achieving only 60% of predicted maximum oxygen uptake [35 ] . However, children with ventricular septal defects, repaired or not, had normal physical activity levels and fully participated in exercise [36 ] . Other studies have shown that repair of the Fontan fenestration improves aerobic and exercise capacity [37] , but some patients showed improvements only in ventilation [38] . Paridon et al. [39 ] showed that although maximal aerobic capacity was reduced, higher oxygen saturation was associated with better exercise performance; boys and adolescents were particularly affected.
Similarly, it appears that children with congenital or acquired cardiomyopathy and those who have undergone cardiac transplantation benefit from a structured and supervised exercise rehabilitation program [34, 40 ] . Two children with idiopathic dilated cardiomyopathy completed a 3-month, hospital-based circuit-training program where their strength, body composition, quality of life and overall activity level improved over baseline [40 ] . Another recent study showed that heart transplant recipients benefited from a home-based exercise rehabilitation program: endurance, peak oxygen consumption, and strength all improved [41] . Both studies showed the programs were safe and feasible in these populations. The potential for deconditioning, along with increased metabolic risk and the likelihood that exercise programs can be beneficial, should also be considered in children with cardiac dysfunction as a result of cancer treatments [42] , renal disease [43] , and HIV infection [44] , to name a few. Miller et al. [44] outline the response to a structured exercise program in children with HIV, a disease that presents metabolic and cardiomyopathic risk.
As discussed in other sections of this article, the prevalence of childhood obesity and its metabolic consequences are now out of control [45] . The risk of atherosclerotic disease in childhood is a real concern. Physical activity and nutrition are key components of any obesity intervention program, and recent studies have shown that those children with metabolic syndrome had a lower Healthy Eating Index and lower physical activity levels [45] . Metabolic syndrome, in turn, is associated with reduced cardiorespiratory fitness, low physical activity, and living in an urban environment [46] . A high-intensity, progressive, resistance training program improved central and whole body adiposity in overweight children, suggesting a conferred risk reduction for cardiometabolic sequelae [47 ] . A Cochrane Review of 26 school-based physical activity programs showed that these programs increased the duration of physical activity and maximum oxygen uptake and reduced television viewing and cholesterol levels [48 ] . Participation in school sports programs substantially increased the number of endothelial progenitor cells, which in turn correlates with improved vascular function and that may protect against cardiovascular disease [49] .
How to study pediatric cardiac problems and to implement evidence-based findings Several recent papers have described models for conducting and improving pediatric cardiac clinical research, such as establishing a clinical research division and conducting registry-based research, both of which have provided infrastructures that have led to investigator successes [50 ,51 ] . Having a formal clinical research infrastructure improves both the planning and conducting of research by refining hypotheses; better controlling error, confounding, and bias; improving the accuracy of data collection and processing; and providing quality checks for analyzing and interpreting data.
The need for more and improved research is driven by the fact that prescribing medications to children in the absence of formal pediatric clinical trails can result in substantial risks to their health; an unfortunate but common occurrence in pediatric cardiology. Pediatric medications must be tested in an ethical and safe environment that is supported by scientific excellence (Topics 3, 12, 15 through 17). In particular, we need to determine whether comparative trials, in which groups of patients are compared to determine the effectiveness of interventions, threaten the application of personalized medicine in pediatric cardiology, in which patient characteristics and individual genomic information are used to craft individual management strategies (Topics 3 through 22) [52 -54 ] . The specialized statistical methods needed to analyze long-term follow-up studies with missing data illustrate the requirements for this kind of research [55 ] . The components needed to develop a comprehensive research agenda, some research priorities, and some proposed directions in research for pediatric cardiology are detailed in the list.
Conclusions
We conclude the following:
(1) Clinical research in pediatric cardiology must accelerate rapidly in the near future if we are to reduce cardiovascular morbidity and mortality for the entire population. [50 ] and expertise in pediatric cardiology clinical research is highly variable and must be strengthened to increase the discovery of both incremental and break-through advances in care. Elevated troponin T, a marker of myocardial injury, was found in 16 of 17 apparently normal infants; two children had troponin T levels consistent with myocardial infarction. Elevated levels were more likely to be found with low birth weight, maternal infection and non-white race. None of these children had cardiac symptoms. Whether this response is pathologic or has long-term consequences is yet to be determined. In a chart review of 48 children with heart failure, a brain natriuretic peptide (BNP) level of greater than 290 pg/ml was 80% sensitive and 87% specific for predicting death, cardiac transplant, or listing for transplant. Serial measures showed that increasing BNP levels were significantly associated with increasing disability.
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